TYRA
Tyra Biosciences, Inc.
Biotechnology
Market Cap$1.77B
5Y Perf.+87.0%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
TYRA vs MRUS
Revenue, margins, valuation, and 5-year total return — side by side.
MRUS
Merus N.V.
Biotechnology
Market Cap$6.83B
5Y Perf.+309.1%
TYRA vs MRUS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | TYRA | MRUS |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $1.77B | $6.83B |
| Revenue (TTM) | $0.00 | $51M |
| Net Income (TTM) | $-120M | $-335M |
| Gross Margin | — | -217.5% |
| Operating Margin | — | -6.5% |
| Total Debt | $6M | $10M |
| Cash & Equiv. | $77M | $293M |
TYRA vs MRUS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
TYRA
MRUS
| Stock | Sep 21 | May 26 | Return |
|---|---|---|---|
| Tyra Biosciences, I… (TYRA) | 100 | 187.0 | +87.0% |
| Merus N.V. (MRUS) | 100 | 409.1 | +309.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: TYRA vs MRUS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: TYRA and MRUS are tied at the top with 2 categories each — the right choice depends on your priorities. Merus N.V. is the stronger pick specifically for growth and revenue expansion and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
TYRA
Tyra Biosciences, Inc.
The Momentum Pick
TYRA has the current edge in this matchup, primarily because of its strength in momentum and efficiency.
- +260.4% vs MRUS's +128.3%
- -38.4% ROA vs MRUS's -43.4%, ROIC -44.8% vs -74.6%
Best for: momentum and efficiency
MRUS
Merus N.V.
The Income Pick
MRUS is the clearest fit if your priority is income & stability and growth exposure.
- beta 0.32
- Rev growth -12.4%, EPS growth -11.7%, 3Y rev CAGR -6.8%
- 8.0% 10Y total return vs TYRA's 26.5%
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | MRUS | -12.4% revenue growth vs TYRA's -38.9% |
| Stability / Safety | MRUS | Beta 0.32 vs TYRA's 0.75, lower leverage |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | TYRA | +260.4% vs MRUS's +128.3% |
| Efficiency (ROA) | TYRA | -38.4% ROA vs MRUS's -43.4%, ROIC -44.8% vs -74.6% |
TYRA vs MRUS — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2024
TYRA vs MRUS — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLMRUSLAGGINGTYRA
TYRATyra Biosciences, Inc.
1leads
MRUSMerus N.V.
3leads
6 Total Categories
CATEGORYLEADERvs TYRAMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
MRUS1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
TYRA5/8
Total Returns1Y, 3Y, 5Y total returns with dividends
MRUS4/6
Risk & VolatilityBeta, volatility, and downside exposure
MRUS2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
MRUS leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
MRUS and TYRA operate at a comparable scale, with $51M and $0 in trailing revenue.
| Metric | TYRATyra Biosciences,… | MRUSMerus N.V. |
|---|---|---|
| RevenueTrailing 12 months | $0 | $51M |
| EBITDAEarnings before interest/tax | -$132M | -$329M |
| Net IncomeAfter-tax profit | -$120M | -$335M |
| Free Cash FlowCash after capex | -$95M | -$318M |
| Gross MarginGross profit ÷ Revenue | — | -2.2% |
| Operating MarginEBIT ÷ Revenue | — | -6.5% |
| Net MarginNet income ÷ Revenue | — | -6.5% |
| FCF MarginFCF ÷ Revenue | — | -6.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -1.9% |
| EPS Growth (YoY)Latest quarter vs prior year | -32.6% | +13.7% |
MRUS leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — TYRA and MRUS each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | TYRATyra Biosciences,… | MRUSMerus N.V. |
|---|---|---|
| Market CapShares × price | $1.8B | $6.8B |
| Enterprise ValueMkt cap + debt − cash | $1.7B | $6.5B |
| Trailing P/EPrice ÷ TTM EPS | -16.37x | -26.87x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 195.71x |
| Price / BookPrice ÷ Book value/share | 7.57x | 8.92x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — TYRA and MRUS each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
TYRA leads this category, winning 5 of 8 comparable metrics.
Profitability & Efficiency
TYRA delivers a -41.2% return on equity — every $100 of shareholder capital generates $-41 in annual profit, vs $-51 for MRUS. MRUS carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to TYRA's 0.02x. On the Piotroski fundamental quality scale (0–9), MRUS scores 4/9 vs TYRA's 1/9, reflecting mixed financial health.
| Metric | TYRATyra Biosciences,… | MRUSMerus N.V. |
|---|---|---|
| ROE (TTM)Return on equity | -41.2% | -50.6% |
| ROA (TTM)Return on assets | -38.4% | -43.4% |
| ROICReturn on invested capital | -44.8% | -74.6% |
| ROCEReturn on capital employed | -43.3% | -48.4% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 4 |
| Debt / EquityFinancial leverage | 0.02x | 0.02x |
| Net DebtTotal debt minus cash | -$72M | -$283M |
| Cash & Equiv.Liquid assets | $77M | $293M |
| Total DebtShort + long-term debt | $6M | $10M |
| Interest CoverageEBIT ÷ Interest expense | — | — |
TYRA leads this category, winning 5 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
MRUS leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in MRUS five years ago would be worth $44,313 today (with dividends reinvested), compared to $12,654 for TYRA. Over the past 12 months, TYRA leads with a +260.4% total return vs MRUS's +128.3%. The 3-year compound annual growth rate (CAGR) favors MRUS at 65.1% vs TYRA's 34.6% — a key indicator of consistent wealth creation.
| Metric | TYRATyra Biosciences,… | MRUSMerus N.V. |
|---|---|---|
| YTD ReturnYear-to-date | +22.8% | 0.0% |
| 1-Year ReturnPast 12 months | +260.4% | +128.3% |
| 3-Year ReturnCumulative with dividends | +143.7% | +350.2% |
| 5-Year ReturnCumulative with dividends | +26.5% | +343.1% |
| 10-Year ReturnCumulative with dividends | +26.5% | +796.4% |
| CAGR (3Y)Annualised 3-year return | +34.6% | +65.1% |
MRUS leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
MRUS leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
MRUS is the less volatile stock with a 0.32 beta — it tends to amplify market swings less than TYRA's 0.75 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. MRUS currently trades 92.6% from its 52-week high vs TYRA's 80.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | TYRATyra Biosciences,… | MRUSMerus N.V. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.75x | 0.32x |
| 52-Week HighHighest price in past year | $40.65 | $97.14 |
| 52-Week LowLowest price in past year | $8.75 | $38.49 |
| % of 52W HighCurrent price vs 52-week peak | +80.9% | +92.6% |
| RSI (14)Momentum oscillator 0–100 | 43.1 | 14.9 |
| Avg Volume (50D)Average daily shares traded | 1.1M | 0 |
MRUS leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates TYRA as "Buy" and MRUS as "Hold". Consensus price targets imply 53.5% upside for TYRA (target: $51) vs -1.5% for MRUS (target: $89).
| Metric | TYRATyra Biosciences,… | MRUSMerus N.V. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Hold |
| Price TargetConsensus 12-month target | $50.50 | $88.69 |
| # AnalystsCovering analysts | 7 | 22 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
MRUS leads in 3 of 6 categories (Income & Cash Flow, Total Returns). TYRA leads in 1 (Profitability & Efficiency). 1 tied.
Best OverallMerus N.V. (MRUS)Leads 3 of 6 categories
Loading custom metrics...
TYRA vs MRUS: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is TYRA or MRUS a better buy right now?
Analysts rate Tyra Biosciences, Inc.
(TYRA) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — TYRA or MRUS?
Over the past 5 years, Merus N.
V. (MRUS) delivered a total return of +343. 1%, compared to +26. 5% for Tyra Biosciences, Inc. (TYRA). Over 10 years, the gap is even starker: MRUS returned +796. 4% versus TYRA's +26. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — TYRA or MRUS?
By beta (market sensitivity over 5 years), Merus N.
V. (MRUS) is the lower-risk stock at 0. 32β versus Tyra Biosciences, Inc. 's 0. 75β — meaning TYRA is approximately 134% more volatile than MRUS relative to the S&P 500. On balance sheet safety, Merus N. V. (MRUS) carries a lower debt/equity ratio of 2% versus 2% for Tyra Biosciences, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — TYRA or MRUS?
On earnings-per-share growth, the picture is similar: Merus N.
V. grew EPS -11. 7% year-over-year, compared to -33. 1% for Tyra Biosciences, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — TYRA or MRUS?
Tyra Biosciences, Inc.
(TYRA) is the more profitable company, earning 0. 0% net margin versus -595. 9% for Merus N. V. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TYRA leads at 0. 0% versus -753. 0% for MRUS. At the gross margin level — before operating expenses — MRUS leads at 37. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — TYRA or MRUS?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is TYRA or MRUS better for a retirement portfolio?
For long-horizon retirement investors, Merus N.
V. (MRUS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 32), +796. 4% 10Y return). Both have compounded well over 10 years (MRUS: +796. 4%, TYRA: +26. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between TYRA and MRUS?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.